Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.04 USD
-0.03 (-1.44%)
Updated Jul 24, 2024 03:56 PM ET
After-Market: $2.04 0.00 (0.00%) 6:40 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CLLS 2.04 -0.03(-1.44%)
Will CLLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLLS
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cellectis (CLLS) Upgraded to Buy: Here's Why
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Other News for CLLS
Cellectis treatment of acute lymphoblastic leukemia granted orphan designation
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Cellectis Shareholders Approve Key Resolutions
Cellectis Shareholders Support Management’s Vision
Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits